CasNo.2222717-52-2,ent-Ertugliflozin;2222717-52-2,(2222717-52-2) Suppliers

10 Milligram	FOB Price: USD 10.0000

Min.Order :10 Milligram
Purity: 99%+ HPLC
Payment Terms : T/T

Keywords

ent-Ertugliflozin 2222717-52-2 C22H25ClO7

Quick Details

Appearance:White to off white powder
Application:experiment research
PackAge:Food bags, aluminum foil bags
ProductionCapacity:5000|Gram|Year
Storage:cool and dry
Transportation:DHL,EMS,TNT,UPS,EMS,by air,by sea;

Superiority:

Advantages
High Purity Guarantee: Confirmed by HPLC with a purity of ≥99.0%, and the structure is verified by NMR (1H, 13C), HRMS, and elemental analysis, providing a reliable basis for studies related to Ertugliflozin.
Good Stability: Stable for 36 months under storage conditions of -20℃ in the dark and sealed. The degradation rate is less than 0.2% in common solvents, ensuring good repeatability of experimental results.

Details:

ent-Ertugliflozin; 2222717-52-2

Product Information

English Name: ent-Ertugliflozin
English Alias: (1R,2R,3R,4S,5R)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS No.: 2242891-20-7
Molecular Formula: C??H??ClO?
Molecular Weight: 436.88

Applications

Drug Research: Used as a reference substance for the separation study of Ertugliflozin enantiomers, facilitating the development of chiral drug analysis methods.
Quality Control: Used for the quality inspection of Ertugliflozin API and formulations, controlling the content of related impurities to ensure that the drug quality meets the standards.
Mechanism Exploration: In the study of drug action mechanisms, it helps analyze the metabolic differences and biological activity differences of its enantiomers in vivo.

Background Description
Ertugliflozin is a drug for treating type 2 diabetes, which reduces blood sugar by inhibiting renal glucose reabsorption. ent-Ertugliflozin, as its enantiomer, may be produced during the synthesis process. The presence of enantiomers may affect the pharmacokinetics, pharmacodynamics, and safety of the drug. With the in-depth research on chiral drugs, the study of ent-Ertugliflozin helps to comprehensively understand the properties of Ertugliflozin and ensure the safety and effectiveness of medication.

Research Status

Detection Technology: Supercritical fluid chromatography (SFC) - MS/MS or high-performance liquid chromatography with chiral columns are used to effectively separate ent-Ertugliflozin from Ertugliflozin, with a limit of detection of 0.002 ng/mL.
Activity Research: In vitro cell experiments show that the affinity of ent-Ertugliflozin for the SGLT2 receptor is lower than that of Ertugliflozin, and its hypoglycemic activity is weaker, but it may have other potential biological activities, and related research is ongoing.
Metabolism Research: Animal experiments have found that the metabolic pathways of ent-Ertugliflozin in vivo partially overlap with those of Ertugliflozin, but the metabolic rates and products are different, and the specific mechanisms remain to be further clarified.